{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:44:33Z","timestamp":1765485873030,"version":"3.48.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":295,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis US LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals SA\/NV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001253","name":"Multiple Myeloma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.ctarc.2025.101025","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T05:22:35Z","timestamp":1761369755000},"page":"101025","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Direct-to-patient research: Opportunity brings challenges"],"prefix":"10.1016","volume":"45","author":[{"given":"Anne","family":"Quinn-Young","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Andreini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niccolo","family":"Pabustan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Schulman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Martillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Wozniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hearn Jay","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Mulligan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2025.101025_bib0001","unstructured":"Myeloma\u2014Cancer stat facts. (2025). SEER. Retrieved October 24, 2025, from https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"issue":"5","key":"10.1016\/j.ctarc.2025.101025_bib0002","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ctarc.2025.101025_bib0003","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ctarc.2025.101025_bib0004","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev., Dis. Primers"},{"issue":"4","key":"10.1016\/j.ctarc.2025.101025_bib0005","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3324\/haematol.2015.129189","article-title":"Treatment of relapsed and refractory multiple myeloma","volume":"101","author":"Sonneveld","year":"2016","journal-title":"Haematologica"},{"issue":"23 Suppl 5","key":"10.1016\/j.ctarc.2025.101025_bib0006","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1093\/neuonc\/noab209","article-title":"Clinical trial challenges, design considerations, and outcome measures in rare CNS tumors","volume":"23","author":"Armstrong","year":"2021","journal-title":"Neuro-Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2025.101025_bib0007","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1158\/1055-9965.EPI-20-1796","article-title":"Epidemiologic research of rare cancers: trends, resources, and challenges","volume":"30","author":"Gallicchio","year":"2021","journal-title":"Cancer Epidemiol. Biomark. Prev.: Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101025_bib0008","doi-asserted-by":"crossref","DOI":"10.1080\/13814788.2023.2273615","article-title":"Direct-to-patient digital diagnostics in primary care: opportunities, challenges, and conditions necessary for responsible digital diagnostics","volume":"29","author":"Villalobos-Quesada","year":"2023","journal-title":"Eur. J. Gen. Pract."},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2025.101025_bib0009","doi-asserted-by":"crossref","first-page":"LBA1519","DOI":"10.1200\/JCO.2016.34.15_suppl.LBA1519","article-title":"The Metastatic Breast Cancer Project: a National direct-to-patient initiative to accelerate genomics research","volume":"34","author":"Wagle","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.101025_bib0010","unstructured":"Count Me In launches a rare cancer research project to engage leiomyosarcoma patients and families. Dana Farber Cancer Institute, 2022 September 21. Retrieved October 24, 2025, from https:\/\/www.dana-farber.org\/newsroom\/news-releases\/2022\/count-me-in-launches-a-rare-cancer-research-project-to-engage-leiomyosarcoma-patients-and-families."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101025_bib0011","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2020-136865","article-title":"A next generation liquid biopsy approach for multiple myeloma","volume":"136","author":"Auclair","year":"2020","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.ctarc.2025.101025_bib0012","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1158\/1078-0432.CCR-23-0746","article-title":"Direct-to-patient clinical trials: one small step or a giant leap?","volume":"29","author":"Desai","year":"2023","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.ctarc.2025.101025_bib0013","article-title":"Count me In: patient-partnered research to address disparities for rare cancer patients","volume":"5","author":"Bhakhri","year":"2024","journal-title":"Ther. Adv. Rare Dis."},{"key":"10.1016\/j.ctarc.2025.101025_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fdgth.2023.1203945","article-title":"Current challenges and potential solutions to the use of digital health technologies in evidence generation: a narrative review","volume":"5","author":"Mumtaz","year":"2023","journal-title":"Front. Digit. Health"},{"issue":"2","key":"10.1016\/j.ctarc.2025.101025_bib0015","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/cpt.2628","article-title":"Opportunities and challenges for decentralized clinical trials: european regulators' Perspective","volume":"112","author":"de Jong","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.ctarc.2025.101025_bib0016","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","article-title":"Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes","volume":"56","author":"Skerget","year":"2024","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.ctarc.2025.101025_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1007087","article-title":"Comprehensive molecular profiling of 718 Multiple myelomas reveals significant differences in mutation frequencies between African and European descent cases","volume":"13","author":"Manojlovic","year":"2017","journal-title":"PLoS Genet."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101025_bib0018","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/leu.2017.197","article-title":"Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma","volume":"32","author":"Lagan\u00e0","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ctarc.2025.101025_bib0019","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-020-00347-6","article-title":"Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis","volume":"10","author":"Derman","year":"2020","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101025_bib0020","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-141930","article-title":"Real-world validity of the revised international staging system in multiple myeloma by race","volume":"136","author":"Notardonato","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2025.101025_bib0021","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JOP.2014.001542","article-title":"Population-based assessment of cancer survivors\u2019 financial burden and quality of life: a prospective cohort study","volume":"11","author":"Zafar","year":"2014","journal-title":"J. Oncol. Pract."},{"issue":"7","key":"10.1016\/j.ctarc.2025.101025_bib0022","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/annonc\/mdz140","article-title":"Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications","volume":"30","author":"Witte","year":"2019","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101025_bib0023","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40271-016-0204-x","article-title":"A systematic review of financial toxicity among cancer survivors: we can't pay the Co-pay","volume":"10","author":"Gordon","year":"2017","journal-title":"Patient"},{"issue":"1","key":"10.1016\/j.ctarc.2025.101025_bib0024","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1182\/blood-2021-148782","article-title":"Interim analysis of Mmrf Curecloud Research Initiative identifies high prevalence and patterns of clonal hematopoiesis of indeterminate potential (CHIP) mutations in a real world myeloma cohort","volume":"138","author":"Jayasinghe","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctarc.2025.101025_bib0025","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1158\/2159-8290.CD-22-0035","article-title":"Classification of KRAS-activating mutations and the implications for therapeutic intervention","volume":"12","author":"Johnson","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ctarc.2025.101025_bib0026","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13063-016-1322-4","article-title":"Participation of the elderly, women, and minorities in pivotal trials supporting 2011\u20132013 US. Food and Drug Administration approvals","volume":"17","author":"Downing","year":"2016","journal-title":"Trials"},{"issue":"3","key":"10.1016\/j.ctarc.2025.101025_bib0027","doi-asserted-by":"crossref","DOI":"10.3399\/BJGPO.2021.0034","article-title":"Ethnicity and socioeconomic status: missing in research means missing in clinical guidance","volume":"5","author":"Beard","year":"2021","journal-title":"BJGP Open"},{"issue":"4","key":"10.1016\/j.ctarc.2025.101025_bib0028","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/107327481602300404","article-title":"Barriers to clinical trial enrollment in racial and Ethnic minority patients with cancer","volume":"23","author":"Hamel","year":"2016","journal-title":"Cancer Control: J. Moffitt Cancer Cent."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225001613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225001613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:35:41Z","timestamp":1765485341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294225001613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":28,"alternative-id":["S2468294225001613"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.101025","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct-to-patient research: Opportunity brings challenges","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.101025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101025"}}